Life sciences are experiencing a shifting landscape of rapid technological innovation, coupled with volatile market conditions that companies in the sector must be ready to adapt to, according to a new analysis by Savills. It’s a landscape being transformed by AI, regulatory uncertainty, rising costs and changing forms of healthcare delivery.
“With 2025 in full swing, life sciences companies face a rapidly evolving landscape filled with both opportunities and significant challenges. Success will depend on strategic adaptation, investment in emerging technologies and a proactive approach to supply chain resilience and healthcare system changes,” commented Austin Barrett, Savills vice chairman and head of life sciences.
Patents on a number of high-revenue drugs will expire this year. This will intensify competition from generics and biosimilars in terms of pricing, market share and patient access. To retain their leadership positions, companies will need to diversify their portfolios through rapid innovation in developing vaccines and specialty medicines, the report said.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
